GlassScriptPhysician profile
Chixin Fang
NPI 1043239528
$5,715.74
in general payments reported to CMS, 2019-2025
21 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,843 · 2020: $482 · 2021: $552 · 2022: $445 · 2023: $843 · 2024: $1,039 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,394.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,230.72 | 2019-2025 | Vemlidy, Epclusa, Livdelzi |
| Abbvie INC. | $628.26 | 2019-2025 | |
| Glaxosmithkline, LLC. | $596.84 | 2019-2024 | Shingrix, Arexvy |
| Amgen INC. | $593.54 | 2019-2025 | Evenity, Prolia, Repatha |
| Merck Sharp & Dohme LLC | $404.01 | 2019-2025 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Exact Sciences Corporation | $292.22 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $185.98 | 2019-2021 | |
| Novo Nordisk INC | $125.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.07 | 2019 | |
| Pfizer INC. | $94.18 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $73.09 | 2025 | Pyrukynd |
| Lilly USA, LLC | $41.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $39.72 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.16 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.31 | 2023 | |
| Phadia US INC. | $23.87 | 2019-2022 | |
| Sanofi Pasteur INC. | $22.27 | 2025 | |
| Ardelyx, INC. | $22.22 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $17.19 | 2020 | |
| Hologic Sales and Service, LLC | $16.58 | 2023 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chixin Fang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.